The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company

The Wall Street JournalTuesday, November 18, 2025 at 10:30:00 AM
The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company
  • Eli Lilly's stock is likely to rise as the market for GLP
  • This development is significant as it highlights the increasing consumer demand for effective weight
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
PositiveFinancial Markets
Eli Lilly and Johnson & Johnson have announced partnerships with AI chipmaker Nvidia, indicating a growing trend among pharmaceutical companies to collaborate with technology firms. This move aims to accelerate drug discovery processes and enhance the efficiency of healthcare workers' workflows.
JPMorgan raises Eli Lilly stock price target to $1,150 on obesity drug outlook
PositiveFinancial Markets
JPMorgan has raised its stock price target for Eli Lilly to $1,150, driven by optimistic projections regarding the company's obesity drug pipeline. This adjustment reflects confidence in the growing market for weight-loss medications, particularly GLP-1 drugs, which are gaining traction among consumers. The positive sentiment surrounding Eli Lilly's potential in this sector indicates a promising outlook for investors.